Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDE...

Descripción completa

Detalles Bibliográficos
Autores: Marchesi, F., Salmanton-García, J., Buquicchio, C., Itri, F., Besson, C., Dávila-Valls, J., Martín-Pérez, S., Fianchi, L., Rahimli, L., Tarantini, G., Grifoni, F.I., Sciume, M., Labrador, J., Cordoba, R., López-García, A., Fracchiolla, N.S., Farina, F., Ammatuna, E., Cingolani, A., García-Bordallo, D., Gräfe, S.K., Bilgin, Y.M., Dargenio, M., González-López, T.J., Guidetti, A., Lahmer, T., Lavilla Rubira, Esperanza, Méndez, G.-A., Prezioso, L., Schönlein, M., Van Doesum, J., Wolf, D., Hersby, D.S., Magyari, F., Van Praet, J., Petzer, V., Tascini, C., Falces-Romero, I., Glenthøj, A., Cornely, O.A., Pagano, L.
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Servizo Galego de Saúde (SERGAS)
Repositorio:RUNA. Repositorio da Consellería de Sanidade e Sergas
OAI Identifier:oai:runa.sergas.gal:20.500.11940/21833
Acceso en línea:https://portalcientifico.sergas.gal//documentos/643af6a51656ab66db7e0700
http://hdl.handle.net/20.500.11940/21833
Access Level:acceso abierto
Palabra clave:Humans
COVID-19
SARS-CoV-2
Hematologic Neoplasms
Antibodies, Monoclonal
Immunization, Passive
Registries
AS Lugo
CHULA
Descripción
Sumario:Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report cases of breakthrough COVID-19 after prophylactic tixagevimab/cilgavimab from the EPICOVIDEHA registry). We identified 47 patients that had received prophylaxis with tixagevimab/cilgavimab in the EPICOVIDEHA registry. Lymphoproliferative disorders (44/47, 93.6%) were the main underlying HM. SARS-CoV-2 strains were genotyped in 7 (14.9%) cases only, and all belonged to the omicron variant. Forty (85.1%) patients had received vaccinations prior to tixagevimab/cilgavimab, the majority of them with at least two doses. Eleven (23.4%) patients had a mild SARS-CoV-2 infection, 21 (44.7%) a moderate infection, while 8 (17.0%) had severe infection and 2 (4.3%) critical. Thirty-six (76.6%) patients were treated, either with monoclonal antibodies, antivirals, corticosteroids, or with combination schemes. Overall, 10 (21.3%) were admitted to a hospital. Among these, two (4.3%) were transferred to intensive care unit and one (2.1%) of them died. Our data seem to show that the use of tixagevimab/cilgavimab may lead to a COVID-19 severity reduction in HM patients; however, further studies should incorporate further HM patients to confirm the best drug administration strategies in immunocompromised patients.

Similares en LA Referencia